Abstract:Selected inhibitors of the BCR/ABL tyrosine kinase have shown a remarkable clinical activity in patients with chronic myelogenous leukemia (CML). However, these drugs do not completely eradicate leukemic cells and drug resistance emerges. Identification of additional contributors to the pathogenesis of CML remains to be important for developing strategies for overcoming resistance to BCR/ABL kinase inhibitors and for eradicating leukemic cells. We and others have previously shown that expression of BCR/ABL in mouse bone marrow cells by retroviral transduction and transplantation (BMT) efficiently induces a CML-like myeloproliferative disorder (MPD). Using this BMT model for CML, we have found that the Grb2 SH2 binding site Y177 of BCR/ABL, which is critical for BCR/ABL to activate the RAS pathway, is required for the induction of CML-like disease by BCR/ABL. We have further shown that oncogenic NRAS (NRASG12D) can rescue the defect of the Y177F mutant BCR/ABL in the induction of CML-like disease. To further elucidate the pathways downstream of NRAS responsible for this “rescue” effect, we utilized three well-characterized NRAS effector mutants, G12D/T35S (activating RAF but is impaired in binding PI3K and RALGEF), G12D/E37G (activating RALGEF but not RAF or PI3K), and G12D/Y40C (activating PI3K but not RAF or RALGEF). None of the three NRAS effector mutants could induce hematological malignancies by themselves, but all were capable of “rescuing” the CML defect of BCR/ABLY177F to some extent. Interestingly, the NRAS G12D/E37G effector mutant was the most efficient. We further examined the role of RALGEF pathway by introducing an activated RALGDSCAAX into our BCR/ABLY177F mouse model. RALGDS-CAAX was able to cooperate with BCR/ABLY177F to induce a CML-like MPD in nearly half of mice whereas RALGDSCAAX alone did not induce diseases in any mice. As a complement to this study, we also introduced dominant negative RAL A or RAL B in the background of BCR/ABL. This resulted in a significant delay in disease onset. Taken together, this data sheds light on the importance of the RALGEF pathway in BCR/ABL-mediated CML induction and supports the notion of inhibition of this pathway as a potential therapeutic strategy.

Inhibition of Small GTPase RalA Regulates Growth and Arsenic-Induced Apoptosis in Chronic Myeloid Leukemia (CML) Cells.

MicroRNA-181a-mediated Downregulation of AC9 Protein Decreases Intracellular Camp Level and Inhibits ATRA-induced APL Cell Differentiation

Mir-181A Post-Transcriptionally Downregulates Oncogenic RalA and Contributes to Growth Inhibition and Apoptosis in Chronic Myelogenous Leukemia (CML)

Single-cell resolution reveals RalA GTPase expanding hematopoietic stem cells and facilitating of BCR-ABL1-driven leukemogenesis in a CRISPR/Cas9 gene editing mouse model

Inhibition Of Erk5 Enhances Cytarabine-Induced Apoptosis In Acute Myeloid Leukemia Cells

As 4 S 4 Targets RING-type E3 Ligase C-Cbl to Induce Degradation of BCR-ABL in Chronic Myelogenous Leukemia

Knockdown of RALA by siRNA inhibits cell proliferation and induces apoptosis in human leukemic K562 cells

Effects of Inactivating Ras-Converting Enzyme or Isoprenylcysteine Carboxyl Methyltransferase in the Pathogenesis of Chronic Myelogenous Leukemia

The role of RAS effectors in BCR/ABL induced chronic myelogenous leukemia

Leukemia-associated Gene MLAA-34 Reduces Arsenic Trioxide-Induced Apoptosis in HeLa Cells Via Activation of the Wnt/β-catenin Signaling Pathway

Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer

Reversal effect of arsenic sensitivity in human leukemia cell line K562 and K562/ADM using realgar transforming solution.

Arsenic Trioxide Inhibits Translation Of Mrna Of Bcr-Abl, Resulting In Attenuation Of Bcr-Abl Levels And Apoptosis Of Human Leukemia Cells

The synergistic effect of miR-203 and cytarabine on the inhibition of cell proliferation and induction of apoptosis in chronic myelogenous leukemia cells

Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide

Arsenic Sulfide Binds C-Cbl To Promote Bcr-Abl Ubiquitination And Degradation In Chronic Myelogenous Leukemia.

The Ralgef Pathway Contributes To The Pathogenesis Of Chronic Myelogenous Leukemia By Bcr/Abl

[Role and Mechanism of the Interaction of BCR-ABL with E3 Ligase C-Cbl in Targeting Therapy of Chronic Myelogenous Leukemia].

The M6a Regulator KIAA1429 Stabilizes RAB27B Mrna and Promotes the Progression of Chronic Myeloid Leukemia and Resistance to Targeted Therapy

CS2164 Suppresses Acute Myeloid Leukemia Cell Growth Via Inhibiting VEGFR2 Signaling in Preclinical Models.

Role Of Signal Regulatory Protein A In Arsenic Trioxide-Induced Promyelocytic Leukemia Cell Apoptosis